Quantcast

Latest Ustekinumab Stories

2015-03-21 08:21:08

- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment

2015-03-20 12:28:02

- Nearly double the percentage of patients on BI 655066 with clear or almost clear skin (PASI 90) after 12 weeks vs.

2015-03-20 12:27:48

- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) (secukinumab) compared to Stelara® (ustekinumab) at Week 16

2015-03-17 16:26:27

Pivotal Results Comparing Brodalumab With Stelara® (Ustekinumab) and Placebo to be Presented in Late-Breaking Session THOUSAND OAKS, Calif., March 17, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)

2015-03-04 16:27:45

AUSTIN, Texas, March 4, 2015 /PRNewswire/ -- XBiotech announced today that results from its Phase II pilot study in patients with moderate to severe plaque psoriasis have been published in JAMA

2015-02-04 08:28:53

Data expected to be released in Q1 2015 PETACH TIKVA, Israel, Feb.

2015-01-21 16:24:42

- Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis EAST HANOVER, N.J., Jan.

2014-12-11 16:24:58

First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.

2014-11-25 16:27:52

Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo THOUSAND OAKS, Calif. and LONDON, Nov.

2014-11-18 08:31:20

Treatment for lifelong skin disease that affects nearly a million Canadians showed significant and clinically meaningful improvements in clinical studies Canadian approval comes


Word of the Day
logocentrism
  • The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.
The word 'logocentrism' is a blend of logo- +‎ centrism.
Related